A complementary strategy leverages the phosphatidylserine‐binding C1C2 peripheral domain of lactadherin.[100, 101, 102] Rountree et al. employed this approach to anchor TAAs, such as PSA and PAP, to EVs, inducing strong antigen‐specific T cell responses and therapeutic tumor control in murine models.[100] This platform has since been extended to antigens such as HER2 and Carcinoembryonic antigen (CEA),[101] demonstrating enhanced immunogenicity and tumor suppression even in antigen‐tolerant transgenic models. The gene discussed is ERBB2; the disease is neoplasm.